R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience

Bašić-Kinda, Sandra; Radman, Ivo; Dujmović, Dino; Ilić, Ivana; Kralik, Marko; Dobrenić, Margareta; Galunić-Bilić, Lea; Rončević, Pavle; Vodanović, Marijo; Sertić, Zrinka; Hude, Ida; Aurer, Igor

doi:10.1007/s00277-020-04353-3

Pregled bibliografske jedinice broj: 1127706

R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front- line regimen with cardiac toxicity: a real-life, single-center experience

Bašić-Kinda, Sandra; Radman, Ivo; Dujmović, Dino; Ilić, Ivana; Kralik, Marko; Dobrenić, Margareta; Galunić-Bilić, Lea; Rončević, Pavle; Vodanović, Marijo; Sertić, Zrinka et al.

R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front- line regimen with cardiac toxicity: a real-life, single-center experience // Annals of hematology, 100 (2021), 6; 1517-1524 doi:10.1007/s00277-020-04353-3 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 1127706 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front- line regimen with cardiac toxicity: a real-life, single-center experience
(R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience)

Autori
Bašić-Kinda, Sandra ; Radman, Ivo ; Dujmović, Dino ; Ilić, Ivana ; Kralik, Marko ; Dobrenić, Margareta ; Galunić-Bilić, Lea ; Rončević, Pavle ; Vodanović, Marijo ; Sertić, Zrinka ; Hude, Ida ; Aurer, Igor

Izvornik
Annals of hematology (0939-5555) 100 (2021), 6; 1517-1524

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
chemotherapy ; etoposide ; lymphoma, large B cell, diffuse ; R-CHOEP ; rituximab

Sažetak
Currently, there is no consensus regarding optimal front-line treatment for younger high- risk patients with large B cell lymphoma. American recommendations list only R-CHOP as standard, while European also include R-ACVBP and R-CHOEP14. We have been routinely using the latter regimen at our institution since 2011 and performed this retrospective real-life single-center study to analyze outcomes. Between September 2011 and April 2019, 66 newly diagnosed patients aged 18 to 60 years with B- large cell lymphoma and high-risk age-adjusted International Prognostic Index score were scheduled to receive 6 or 8 cycles of bi- weekly chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, etoposide, steroids, and rituximab (R-CHOEP14). After a median follow-up of 4.7 years, the estimated 3-year progression-free survival was 87% (95% CI 80- 96%) and 3-year overall survival 90% (95% CI 83-98%). Grade ≥ 3 hematological side effects occurred in 83% and infectious in 41% of patients ; one patient died of toxicity. Grade ≥ 2 cardiac toxicity occurred in 21% of patients, more frequently than previously reported. The cumulative 5-year risk of congestive heart failure with all-cause mortality as the competing risk was 17%. R-CHOEP14 is a very effective and manageable regimen for younger high- risk patients with B-large cell lymphoma, but the risk of cardiotoxicity warrants further investigations.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA

Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Profili:

Ivana Ilić (autor)